Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Argus Health
Express Scripts
Merck
US Army
Queensland Health
McKinsey
Deloitte
Accenture

Generated: May 22, 2018

DrugPatentWatch Database Preview

Inspra Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Inspra patents expire, and when can generic versions of Inspra launch?

Inspra is a drug marketed by Gd Searle Llc and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-two patent family members in twenty-nine countries.

The generic ingredient in INSPRA is eplerenone. There are four drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the eplerenone profile page.
Summary for Inspra
Drug patent expirations by year for Inspra
Pharmacology for Inspra
Synonyms for Inspra
(+)-Eplerenone
(7?,11?,17?)-9,11-Epoxy-17-hydroxy-3-oxo-pregn-4-ene-7,21-dicarboxylic acid ?-lactone methyl ester
107724-20-9
54272-EP2270011A1
54272-EP2298779A1
54272-EP2308562A2
6995V82D0B
7alpha-methoxycarbonyl-3-oxo-9,11alpha-epoxy-17alpha-pregn-4-ene-21,17-carbolactone
9,11alpha-Epoxy-17-hydroxy-3-oxo-17alpha-pregn-4-ene-7alpha,21-dicarboxylic Acid gamma-Lactone Methyl Ester
9,11alpha-Epoxy-17-hydroxy-3-oxo-17alpha-pregn-4-ene-7alpha,21-dicarboxylic acid, gamma-lactone, methyl ester
AB01274707_02
AB01274707-01
AB2000235
AC-4213
AC1L9FDC
AKOS015962307
AX8041152
BC210409
BDBM50318300
C12512
CAS-107724-20-9
Cgp 30083
CGP-30083
CGP30083
CHEBI:31547
CHEMBL1095097
CS-2231
D01115
D0Q4SD
DB00700
DR002506
DSSTox_CID_26094
DSSTox_GSID_46094
DSSTox_RID_81333
DTXSID2046094
E0905
Epleremone
Eplerenone
Eplerenone (JAN/USAN/INN)
Eplerenone (JP17/USAN/INN)
Eplerenone [USAN:INN:BAN]
Eplerenone [USAN]
Eplerenone, >=98% (HPLC)
Epoxymexrenone
Epoxymexrenone;CGP30083;SC-66110
GTPL2876
HSDB 7522
HY-B0251
Inspra (TN)
Inspra, Epoxymexrenone, CGP30083, SC-66110,Eplerenone
JUKPWJGBANNWMW-VWBFHTRKSA-N
KS-1406
methyl (1'R,2R,2'S,9'R,10'R,11'S,15'S,17'R)-2',15'-dimethyl-5,5'-dioxo-18'-oxaspiro[oxolane-2,14'-pentacyclo[8.8.0.0^{1,17}.0^{2,7}.0^{11,15}]octadecan]-6'-ene-9'-carboxylate
methyl (1'R,2R,2'S,9'R,10'R,11'S,15'S,17'R)-2',15'-dimethyl-5,5'-dioxo-18'-oxaspiro[oxolane-2,14'-pentacyclo[8.8.0.0;{1,17}.0;{2,7}.0;{11,15}]octadecan]-6'-ene-9'-carboxylate
METHYL (1'R,2R,2'S,9'R,10'R,11'S,15'S,17'R)-2',15'-DIMETHYL-5,5'-DIOXO-18'-OXASPIRO[OXOLANE-2,14'-PENTACYCLO[8.8.0.0(1),(1)?.0(2),?.0(1)(1),(1)?]OCTADECAN]-6'-ENE-9'-CARBOXYLATE
methyl (4aS,4bR,5aR,6aS,7R,9aS,9bR,10R)-4a,6a-dimethyl-2,5'-dioxo-2,4,4a,4',5a,5',6,6a,8,9,9a,9b,10,11-tetradecahydro-3H,3'H-spiro[cyclopenta[1,2]phenanthro[4,4a-b]oxirene-7,2'-furan]-10-ca
methyl dimethyl-5'-dioxo-spiro[[?]-[?],2'-tetrahydrofuran]carboxylate
MolPort-003-986-216
NCGC00159559-02
NCGC00159559-03
PL041004
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, gamma-lactone, methyl ester, (7alpha,11alpha,17alpha)-
s1707
SC 6110
SC-66110
SC-6611O
SCHEMBL21515
Selara
SR-01000942233
SR-01000942233-1
TL8000270
Tox21_111746
Tox21_111746_1
UNII-6995V82D0B
YNU
ZINC3985982

US Patents and Regulatory Information for Inspra

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-001 Sep 27, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-003 Sep 27, 2002 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-001 Sep 27, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-001 Sep 27, 2002 AB RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for Inspra

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-001 Sep 27, 2002 ➤ Sign Up ➤ Sign Up
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-003 Sep 27, 2002 ➤ Sign Up ➤ Sign Up
Gd Searle Llc INSPRA eplerenone TABLET;ORAL 021437-002 Sep 27, 2002 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for INSPRA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 25 mg and 50 mg ➤ Subscribe 2006-09-27

Non-Orange Book US Patents for Inspra

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,592,902 Controlled release eplerenone compositions ➤ Sign Up
6,863,902 Immediate release eplerenone compositions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Supplementary Protection Certificates for Inspra

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
04C/008 Belgium ➤ Sign Up PRODUCT NAME: EPLERENONE; NATIONAL REGISTRATION NO/DATE: 241 IS 188 F3 20041220; FIRST REGISTRATION: NL RVG 29963 20040316
1135139/01 Switzerland ➤ Sign Up FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Mallinckrodt
Harvard Business School
US Army
Queensland Health
Medtronic
McKinsey
Farmers Insurance
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.